MedTrace Logo

Intravenous Metoprolol in Septic Shock

NCT06592547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-01-29

No results posted yet for this study

Summary

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

Conditions

  • Septic Shock
  • Ventilator Acquired Pneumonia

Interventions

DRUG

Intravenous metoprolol tartrate

An intravenous beta-blockers, recieved FDA approval

OTHER

Standard Care (in control arm)

Standard care according to surviving sepsis campaign

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-12-01
Completion
2024-11-10
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592547 on ClinicalTrials.gov